All News

    Understanding the Distinction Between HER2-Low and HER2-Ultralow Breast Cancer

    February 17th 2025, 10:00pm

    Video

    Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

    Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC

    February 17th 2025, 8:00pm

    Article

    Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

    Rediscovering My Sense of Faith Following a Colon Cancer Diagnosis

    February 17th 2025, 6:00pm

    Article

    Faith, from my perspective, is believing in the unseen, and was something I rediscovered following my colon cancer diagnosis.

    An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment

    February 17th 2025, 5:00pm

    Video

    Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.

    mpMRI Improves Initial Staging in Suspected Muscle-Invasive Bladder Cancer

    February 17th 2025, 4:01pm

    Article

    Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of bladder tumor was beneficial.

    GAP Regimen May Not Improve Survival in Biliary Tract Cancer Subset

    February 17th 2025, 2:00pm

    Article

    The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

    Treatment Intensification Adoption Differences Across Prostate Cancer

    February 16th 2025, 7:00pm

    Video

    There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.

    EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer

    February 16th 2025, 3:00pm

    Article

    Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.

    Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset

    February 15th 2025, 10:52pm

    Article

    Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.

    Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma

    February 15th 2025, 10:36pm

    Article

    Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.